How a Diabetes Drug Became a Global Phenomenon Semaglutide belongs to a class of drugs called GLP-1 receptor agonists, which work by mimicking a gut hormone that regulates both blood sugar and appetite. Dr. Akunga, a Kenyan physician who has spoken publicly on the drug's use, explained the regulatory history: "Because it was originally only licensed for type 2 diabetes, the manufacturer had to conduct new clinical studies using the same molecule in order to seek approval for weight loss as a separate indication." That original diabetes indication is what makes Ozempic's inclusion on WHO's essential medicines list significant, but it's also what makes the drug's runaway popularity for weight loss, fueled heavily by social media, a complicating factor in how it's actually being distributed and sold across African markets. What Reporting Found in Nairobi's Pharmacies A Daily Nation investigation into Nairobi's Central Business District found how easily the drug can be obtained without a prescription or any verification of diabetic status. At one pharmacy near Odeon Cinema, a pharmacist offered to source the drug through suppliers without asking whether the buyer was diabetic, quoting prices ranging from Ksh65,000 to Ksh105,000 depending on the supplier, well above even the drug's already-high official price. Kenya's Poisons and Pharmacy Board (PPB) has warned that anyone found distributing counterfeit medicine faces fines up to Ksh1 million and up to two years imprisonment, and issued a public alert in July 2024 after an Interpol report flagged falsified Ozempic pens circulating internationally, insulin pens for a different drug entirely, relabeled as Ozempic. The PPB says it has not traced those specific falsified pens to the Kenyan market, but the broader unregulated supply chain reporters encountered suggests the risk hasn't gone away. The Scale of the Underlying Disease Burden The stakes behind the pricing and access problem are substantial. The International Diabetes Federation estimates 25 million adults across Africa live with diabetes, while roughly 18 million more remain undiagnosed, meaning the continent's actual diabetes burden is likely far larger than official case counts suggest. For the patients this drug is actually intended to treat, high prices, weak insurance coverage, and limited public-sector access have kept newer diabetes medicines like semaglutide effectively out of reach for most households, even as demand for its off-label weight-loss use grows largely unregulated. Patent Expiry Is Starting to Shift the Picture, But Slowly Novo Nordisk's primary patent covering semaglutide expired in South Africa in March 2026, opening the door for rival drugmakers to seek approval for competing versions, and at least 12 Ozempic generics are reportedly under review in what's described as Africa's most developed pharmaceutical market. Novo Nordisk itself responded by launching an authorized copy called Extensior in South Africa, using the identical active ingredient, manufacturing process and delivery device as Ozempic but sold under a different name, at a 15% discount. Sara Norcross, General Manager of Novo Nordisk South Africa, framed the move as being about access: "We will continue to assess pricing as our goal is always to improve access by providing patients and healthcare professionals with additional treatment options but ensuring that we maintain the same high quality standards." Why a 15% Discount Isn't Being Read as a Breakthrough Reporting on the South African price cut has been notably unimpressed by its scale. Discovery Health, the medical scheme administrator that typically leads industry decisions on covering costly new treatments, indicated it has no immediate plans to expand eligibility criteria for its largest client scheme based on the discount alone, a signal that even a 15% reduction doesn't meaningfully close the affordability gap for most patients. Separately, Mediscor's 2024 Medicines Review found Ozempic spending had surged from position 170 in 2023 to position 12 in 2024 on its list of top drivers of medical scheme spending in South Africa, evidence that even at current high prices, demand, and the resulting cost burden on insurers, keeps climbing. What This Means for Kenya Specifically Kenya's patent situation and pricing trajectory haven't been reported with the same clarity as South Africa's, but the underlying dynamics, patent protection keeping prices artificially high, an unregulated grey and black market filling the resulting gap, and a genuine, undertreated diabetes burden, are the same across the region. Whether Kenya sees its own patent expiries, generic approvals, or price movements on a similar timeline to South Africa's will determine whether WHO's essential-medicine designation actually translates into affordable access here, or whether the gap between global classification and local reality persists, with Nairobi's pharmacies continuing to fill the difference through channels the country's own drug regulator has already flagged as risky. _Reporting sources: Daily Nation (Nairobi pharmacy investigation); Willow Health Media; Business Daily Africa (10 April 2026); The Radical Leap Group (July 2026); Business Day South Africa (24 July 2026); AllAfrica / Spotlight (4 February 2026); International Diabetes Federation; Kenya Poisons and Pharmacy Board. No photo attached to this piece._